Japan's unapproved drug support center

7 June 2009

The Unapproved Drugs Development Support Center (a tentative name for the new organization), which will support domestic research, development  and production of medicines that have not been approved for use in  Japan financially and technically, has now been formally established in  order to eliminate the so-called, "drug-lag," the Japan Pharmaceutical  Manufacturers Association announced. A project team to act on this  issue was convened earlier this year (Marketletter January 26).

The set up consists of 69 JPMA member companies. Fumimaro Takaku,  president of the Japanese Association of Medical Sciences and also of  the Jichi Medical School, has been appointed to the role of president of  the new Center. It has said that the JPMA is aiming to demonstrate the  manufacturers' efforts to eliminate the drug-lag as the producer-side an  attempt to introduce a new National Health Insurance drug pricing  system, or a drug price maintenance exception system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight